Department of Pharmacology, Unit of Clinical Pharmacology and Therapeutic Oncology, Medical School, National and Kapodistrian University of Athens.
Departments of Oncology.
J Immunother. 2018 Jul/Aug;41(6):300-305. doi: 10.1097/CJI.0000000000000221.
Penile squamous cell carcinoma (PeSCC) is a rare tumor and advanced PeSCC is associated with poor survival due to the aggressiveness of the disease and lack of effective systemic therapies. We describe for the first time a case with advanced chemoradiation refractory PeSCC who had documented response to active immunotherapy with the immune checkpoint inhibitor, anti-programmed death-1 monoclonal antibody Nivolumab. The patient suffered from a poor prognosis human papillomavirus-negative PeSCC, with a somatic inactivation mutation of cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in tumor cells, and treatment with Nivolumab resulted in a partial response to therapy and significant tumor shrinkage. Histology transitions and alterations in tumor-infiltrating cytotoxic CD8 T-cell lymphocytes, programmed death ligand-1 expression on tumor cells and immune cells in tumor lesion biopsies pretreatment and posttreatment with Nivolumab were observed and described. In conclusion, in patients with metastatic PeSCC active immunotherapy combinations with an anti-programmed death-1/programmed death ligand-1 agent may be beneficial and further relative clinical studies are required.
阴茎鳞状细胞癌（PeSCC）是一种罕见的肿瘤，由于疾病的侵袭性和缺乏有效的全身治疗，晚期 PeSCC 患者的生存率较差。我们首次描述了一例晚期放化疗耐药的 PeSCC 患者，该患者对免疫检查点抑制剂抗程序性死亡-1 单克隆抗体纳武利尤单抗的主动免疫治疗有明确的反应。该患者患有预后不良的人乳头瘤病毒阴性 PeSCC，肿瘤细胞中存在细胞周期蛋白依赖性激酶抑制剂 2A（CDKN2A）基因的体细胞失活突变，纳武利尤单抗治疗导致部分缓解和肿瘤明显缩小。观察并描述了肿瘤病变活检标本中肿瘤浸润细胞毒性 CD8 T 淋巴细胞、肿瘤细胞和免疫细胞程序性死亡配体-1 表达的组织学转变和改变。总之，对于转移性 PeSCC 患者，抗程序性死亡-1/程序性死亡配体-1 药物的主动免疫治疗联合治疗可能有益，需要进一步的相关临床研究。
